A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO)

NCT05533775 PHASE1, PHASE2 RECRUITING

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	65
Start date	Wed Nov 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Nov 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Mature B-Cell Non-Hodgkin Lymphoma

Interventions

• Obinutuzumab
• Glofitamab
• Rituximab
• Ifosfamide
• Carboplatin
• Etoposide
• Tocilizumab

Countries

Denmark, France, Italy, Germany, Hungary, Poland, South Korea, Australia, China, Spain, United States, Brazil, Czechia